New Research Reveals That Drinking Coffee Could Prevent Heart Disease

Moderate coffee or caffeine consumption may lower the risk of developing multiple cardiometabolic diseases, according to research using UK Biobank data. Consuming 3 cups of coffee or 200-300 mg of caffeine daily was linked to a reduced risk of cardiometabolic multimorbidity.

According to new research published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism, regularly consuming moderate amounts of coffee and caffeine may help protect against the development of various cardiometabolic diseases, such as type 2 diabetes, coronary heart disease, and stroke.

Researchers found that regular coffee or caffeine intake, especially at moderate levels, was associated with a lower risk of new-onset cardiometabolic multimorbidity (CM), which refers to the coexistence of at least two cardiometabolic diseases.

The prevalence of individuals with multiple cardiometabolic diseases, or CM, is becoming an increasing public health concern as populations age around the world, notes the study.

Coffee and caffeine consumption could play an important protective role in almost all phases of CM development, researchers found.

“Consuming three cups of coffee, or 200-300 mg caffeine, per day might help to reduce the risk of developing cardiometabolic multimorbidity in individuals without any cardiometabolic disease,” said the study’s lead author Chaofu Ke, M.D., Ph.D., of the Department of Epidemiology and Biostatistics, School of Public Health at Suzhou Medical College of Soochow University, in Suzhou, China.

The study found that compared with non-consumers or consumers of less than 100mg caffeine per day, consumers of a moderate amount of coffee (3 drinks per day) or caffeine (200-300 mg per day) had a 48.1% or 40.7% reduced risk for new-onset CM.

Ke and his colleagues based their findings on data from the UK Biobank, a large and detailed longitudinal dietary study with over 500,000 participants aged 37-73 years. The study excluded individuals who had ambiguous information on caffeine intake. The resulting pool of participants included a total of 172,315 individuals who were free of any cardiometabolic diseases at baseline for the analyses of caffeine, and a corresponding 188,091 individuals for the analyses of coffee and tea consumption.

The participants’ cardiometabolic diseases outcomes were identified from self-reported medical conditions, primary care data, linked inpatient hospital data, and death registry records linked to the UK Biobank.

Coffee and caffeine intake at all levels were inversely associated with the risk of new-onset CM in participants without cardiometabolic diseases. Those who reported moderate coffee or caffeine intake had the lowest risk, the study found. Moderate coffee or caffeine intake was inversely associated with almost all developmental stages of CM.

“The findings highlight that promoting moderate amounts of coffee or caffeine intake as a dietary habit to healthy people might have far-reaching benefits for the prevention of CM,” Ke said.

Addressing a Research Gap

Numerous epidemiological studies have revealed the protective effects of coffee, tea, and caffeine consumption on morbidity of single cardiometabolic diseases. However, the potential effects of these beverages on the development of CM were largely unknown.

The authors reviewed the available research on this topic and found people with a single cardiometabolic disease may have a two-fold higher all-cause mortality risk than those free of any cardiometabolic diseases. By contrast, the researchers found individuals with CM may have an almost 4 to 7 times higher risk of all-cause mortality. The researchers also noted that CM may present higher risks of loss of physical function and mental stress than those with single diseases.

Reference: “Habitual Coffee, Tea, and Caffeine Consumption, Circulating Metabolites, and the Risk of Cardiometabolic Multimorbidity” by Xujia Lu, Xiaohong Zhu, Guochen Li, Luying Wu, Liping Shao, Yulong Fan, Chen-Wei Pan, Ying Wu, Yan Borné and Chaofu Ke, 17 September 2024, The Journal of Clinical Endocrinology & Metabolism.
DOI: 10.1210/clinem/dgae552

Other study authors include: Xujia Lu, Guochen Li, Luying Wu, Liping Shao, Yulong Fan, and Chen-Wei Pan of Soochow University; Xiaohong Zhu of Suzhou Centers for Disease Control and Prevention in Suzhou, China; Ying Wu of the Southern Medical University in Guangzhou, China; and Yan Borné of Lund University in Malmö, Sweden.

The National Natural Science Foundation of China, the Project of MOE Key Laboratory of Geriatric Diseases and Immunology, and the Research on Key Technologies for the Prevention and Control of Major Diseases and Infectious Diseases in Suzhou funded the study.

Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.